| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Piceatannol (also known as Astringenin; NSC-622471; trans-Piceatannol), a naturally occuring stilbene, is a potent and selective Syk inhibitor and shows ~10-fold selectivity for Srk over Lyn. It has anti-inflammatory, immunomodulatory and antiproliferative activities. Piceatannol demonstrated high in vivo anti-inflammatory activity in female BALB/c mice with dextran sulfate sodium (DSS)-induced colitis. It inhibits p56lck and syk protein tyrosine kinases and inhibits TNF-induced NF-κB activation and gene expression. Synthesis results from conversion of resveratrol by cytochrome P450 1B1.
| ln Vitro |
One metabolite of resveratrol is piceatannol [2]. Six diffuse large B-cell lymphoma (DLBCL) cell lines (SUDHL-6, U2392, DOHH2, Karpas 422, VAL, OCI Ly19) have their cell growth inhibited by the SYK inhibitor Piceatannol (3.125, 6.25, 12.5, 25 and 50 μM; 72 hours); the IC50 values for these cell lines are 18 μM, 25 μM, 37 μM, 48 μM, and >50 μM, respectively [3].
|
|---|---|
| ln Vivo |
Piceatannol (10, 20 and 40 mg/kg) suppresses the infiltration of inflammatory cells generated by lipopolysaccharide and prevents pulmonary edema [1]. In lung tissue, piceatannol (10, 20, and 40 mg/kg) reduces myeloperoxidase activity and prevents the synthesis of iNOS and COX-2 expression that is produced by lipopolysaccharide [1]. By preventing the activation of the TLR/NF-κB signaling pathway in lung tissue, piceatannol (10, 20, and 40 mg/kg; intraperitoneally injected for 1 hour) therapy decreased the inflammatory response during LPS-induced acute lung injury (ALI) [1].
|
| Cell Assay |
Cell Cytotoxicity Assay[3]
Cell Types: Six DLBCL cell lines (Karpas 422, VAL, SUDHL-6, OCI Ly19, U2392 and DOHH2) Tested Concentrations: 3.125, 6.25, 12.5, 25, and 50 μM Incubation Duration: 72 hrs (hours) Experimental Results: The IC50s were 18 μM in SUDHL-6, 25 μM in U2392, 37 mM in DOHH2, 48 μM in Karpas 422 and higher than 50 μM in OCI-Ly19 and in VAL. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6 mice (40-50 g)[1]
Doses: 10, 20, and 40 mg/kg Route of Administration: Intraperitoneally 1 h before LPS challenge Experimental Results: Dramatically decreased the pulmonary edema induced by LPS. |
| References |
[1]. Lu-Yuan Peng,et al. Protective Effect of Piceatannol Against Acute Lung Injury Through Protecting the Integrity of Air-Blood Barrier and Modulating the TLR4/NF-κB Signaling Pathway Activation. Front Pharmacol. 2020 Jan 22;10:1613.
[2]. Jonathan Kershaw, et al. The Therapeutic Potential of Piceatannol, a Natural Stilbene, in Metabolic Diseases: A Review. J Med Food. 2017 May;20(5):427-438. [3]. Andrea Rinaldi, et al. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.Hematol Oncol. 2011 Sep;29(3):164-6. [4]. Kamila Siedlecka-Kroplewska, et al. Induction of autophagy, apoptosis and aquisition of resistance in response to piceatannol toxicity in MOLT-4 human leukemia cells. Toxicol In Vitro. 2019 Sep;59:12-25. |
| Molecular Formula |
C14H12O4
|
|
|---|---|---|
| Molecular Weight |
244.24
|
|
| CAS # |
10083-24-6
|
|
| Related CAS # |
|
|
| SMILES |
c1(c(ccc(\C=C\c2cc(O)cc(c2)O)c1)O)O
|
|
| InChi Key |
CDRPUGZCRXZLFL-OWOJBTEDSA-N
|
|
| InChi Code |
InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+
|
|
| Chemical Name |
(E)-4-[2-(3,5Dihydroxyphenyl)ethenyl]1,2-benzenediol, 3,3′,4,5′-Tetrahydroxy-trans-stilbene
|
|
| Synonyms |
NSC 622471; NSC-622471; Piceatannol; NSC622471.
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0943 mL | 20.4717 mL | 40.9433 mL | |
| 5 mM | 0.8189 mL | 4.0943 mL | 8.1887 mL | |
| 10 mM | 0.4094 mL | 2.0472 mL | 4.0943 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Int Immunopharmacol.2008 Dec 10;8(12):1695-702. |
Int Immunopharmacol. 2008 Dec 10;8(12):1695-702. |
Int Immunopharmacol. 2008 Dec 10;8(12):1695-702. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
